Literature DB >> 29581113

Chemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract.

Bruno Corsini1, Roberto Díez-Martínez2, Leire Aguinagalde1, Fernando González-Camacho1, Esther García-Fernández2, Patricia Letrado2, Pedro García3,4, Jose Yuste5,4.   

Abstract

Bacteriophage-borne lytic enzymes, also named lysins or enzybiotics, are efficient agents for the killing of bacterial pathogens. The colonization of the respiratory tract by Streptococcus pneumoniae is a prerequisite for the establishment of the infection process. Hence, we have evaluated the antibacterial activities of three different lysins against pneumococcal colonization using human nasopharyngeal and lung epithelial cells as well as a mouse model of nasopharyngeal colonization. The lysins tested were the wild-type Cpl-1, the engineered Cpl-7S, and the chimera Cpl-711. Moreover, we included amoxicillin as a comparator antibiotic. Human epithelial cells were infected with three different multidrug-resistant clinical isolates of S. pneumoniae followed by a single dose of the corresponding lysin. The antimicrobial activities of these lysins were also evaluated using a mouse nasopharyngeal carriage model. The exposure of the infected epithelial cells to Cpl-7S did not result in the killing of any of the pneumococcal strains investigated. However, the treatment with Cpl-1 or Cpl-711 increased the killing of S. pneumoniae organisms adhered to both types of human epithelial cells, with Cpl-711 being more effective than Cpl-1, at subinhibitory concentrations. In addition, a treatment with amoxicillin had no effect on reducing the carrier state, whereas mice treated by the intranasal route with Cpl-711 showed significantly reduced nasopharyngeal colonization, with no detection of bacterial load in 20 to 40% of the mice. This study indicates that Cpl-1 and Cpl-711 lysins might be promising antimicrobial candidates for therapy against pneumococcal colonization.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  mouse model; nasopharyngeal colonization; phage lysins; pneumococcus

Mesh:

Substances:

Year:  2018        PMID: 29581113      PMCID: PMC5971604          DOI: 10.1128/AAC.02212-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  49 in total

1.  Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase.

Authors:  J M Loeffler; D Nelson; V A Fischetti
Journal:  Science       Date:  2001-12-07       Impact factor: 47.728

2.  A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae.

Authors:  Roberto Díez-Martínez; Héctor D De Paz; Esther García-Fernández; Noemí Bustamante; Chad W Euler; Vincent A Fischetti; Margarita Menendez; Pedro García
Journal:  J Antimicrob Chemother       Date:  2015-03-01       Impact factor: 5.790

Review 3.  Bacteriophage lysins as effective antibacterials.

Authors:  Vincent A Fischetti
Journal:  Curr Opin Microbiol       Date:  2008-10-14       Impact factor: 7.934

4.  Streptococcus pneumoniae pharyngeal colonization in school-age children and adolescents with cancer.

Authors:  Nicola Principi; Valentina Preti; Stefania Gaspari; Antonella Colombini; Marco Zecca; Leonardo Terranova; Maria Giuseppina Cefalo; Valentina Ierardi; Claudio Pelucchi; Susanna Esposito
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 5.  Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease.

Authors:  Angela E Rankine-Mullings; Shirley Owusu-Ofori
Journal:  Cochrane Database Syst Rev       Date:  2017-10-10

6.  Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia.

Authors:  Martin Witzenrath; Bernd Schmeck; Jan M Doehn; Thomas Tschernig; Janine Zahlten; Jutta M Loeffler; Maren Zemlin; Holger Müller; Birgitt Gutbier; Hartwig Schütte; Stefan Hippenstiel; Vincent A Fischetti; Norbert Suttorp; Simone Rosseau
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

7.  Antibiotic susceptibility and molecular epidemiology of nasopharyngeal pneumococci from Spanish children.

Authors:  D Sánchez-Tatay; L A Arroyo; D Tarragó; M J Lirola; A Porras; A Fenoll; W P Hausdorff; A B Brueggemann; I Obando
Journal:  Clin Microbiol Infect       Date:  2008-08       Impact factor: 8.067

8.  Rates of pneumococcal disease in adults with chronic medical conditions.

Authors:  Kimberly M Shea; John Edelsberg; Derek Weycker; Raymond A Farkouh; David R Strutton; Stephen I Pelton
Journal:  Open Forum Infect Dis       Date:  2014-05-27       Impact factor: 3.835

9.  The human milk protein-lipid complex HAMLET sensitizes bacterial pathogens to traditional antimicrobial agents.

Authors:  Laura R Marks; Emily A Clementi; Anders P Hakansson
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

10.  PL3 Amidase, a Tailor-made Lysin Constructed by Domain Shuffling with Potent Killing Activity against Pneumococci and Related Species.

Authors:  Blas Blázquez; Alba Fresco-Taboada; Manuel Iglesias-Bexiga; Margarita Menéndez; Pedro García
Journal:  Front Microbiol       Date:  2016-07-28       Impact factor: 5.640

View more
  8 in total

Review 1.  Antimicrobial resistance in nephrology.

Authors:  Tina Z Wang; Rosy Priya L Kodiyanplakkal; David P Calfee
Journal:  Nat Rev Nephrol       Date:  2019-08       Impact factor: 28.314

2.  ClyJ Is a Novel Pneumococcal Chimeric Lysin with a Cysteine- and Histidine-Dependent Amidohydrolase/Peptidase Catalytic Domain.

Authors:  Hang Yang; Yujing Gong; Huaidong Zhang; Irina Etobayeva; Paulina Miernikiewicz; Dehua Luo; Xiaohong Li; Xiaoxu Zhang; Krystyna Dąbrowska; Daniel C Nelson; Jin He; Hongping Wei
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 3.  Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy.

Authors:  Hugo Oliveira; Carlos São-José; Joana Azeredo
Journal:  Viruses       Date:  2018-05-29       Impact factor: 5.048

4.  Safety Studies of Pneumococcal Endolysins Cpl-1 and Pal.

Authors:  Marek Harhala; Daniel C Nelson; Paulina Miernikiewicz; Ryan D Heselpoth; Beata Brzezicka; Joanna Majewska; Sara B Linden; Xiaoran Shang; Aleksander Szymczak; Dorota Lecion; Karolina Marek-Bukowiec; Marlena Kłak; Bartosz Wojciechowicz; Karolina Lahutta; Andrzej Konieczny; Krystyna Dąbrowska
Journal:  Viruses       Date:  2018-11-15       Impact factor: 5.048

5.  Methylation Warfare: Interaction of Pneumococcal Bacteriophages with Their Host.

Authors:  Leonardo Furi; Liam A Crawford; Guillermo Rangel-Pineros; Ana S Manso; Megan De Ste Croix; Richard D Haigh; Min J Kwun; Kristine Engelsen Fjelland; Gregor D Gilfillan; Stephen D Bentley; Nicholas J Croucher; Martha R Clokie; Marco R Oggioni
Journal:  J Bacteriol       Date:  2019-09-06       Impact factor: 3.490

Review 6.  Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics.

Authors:  Jayaseelan Murugaiyan; P Anand Kumar; G Srinivasa Rao; Katia Iskandar; Stephen Hawser; John P Hays; Yara Mohsen; Saranya Adukkadukkam; Wireko Andrew Awuah; Ruiz Alvarez Maria Jose; Nanono Sylvia; Esther Patience Nansubuga; Bruno Tilocca; Paola Roncada; Natalia Roson-Calero; Javier Moreno-Morales; Rohul Amin; Ballamoole Krishna Kumar; Abishek Kumar; Abdul-Rahman Toufik; Thaint Nadi Zaw; Oluwatosin O Akinwotu; Maneesh Paul Satyaseela; Maarten B M van Dongen
Journal:  Antibiotics (Basel)       Date:  2022-02-04

Review 7.  How Good are Bacteriophages as an Alternative Therapy to Mitigate Biofilms of Nosocomial Infections.

Authors:  Aditi Singh; Sudhakar Padmesh; Manish Dwivedi; Irena Kostova
Journal:  Infect Drug Resist       Date:  2022-02-17       Impact factor: 4.003

Review 8.  Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials.

Authors:  Roberto Vázquez; Ernesto García; Pedro García
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.